CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 5, 2014--
AVEO Oncology (NASDAQ: AVEO) today announced that the company will
release its financial results for the first quarter ended March 31, 2014
after market close on Wednesday, May 7, 2014.
Management plans to host financial results conference calls on a
semi-annual basis, with the Company’s next conference call in August
2014. At that time, the Company will review its mid-year financial
results and provide an update on its corporate strategy. In the interim,
AVEO continues to welcome communications from shareholders throughout
the year as the Company seeks to continue to execute against its 2014
strategic plan and objectives.
Further details about the Company’s business and financial results will
be available in a Quarterly Report on Form 10-Q to be filed with the
Securities and Exchange Commission after Q1 financial results are
AVEO Oncology (NASDAQ: AVEO) is a biopharmaceutical company committed to
discovering and developing targeted therapies designed to provide
substantial impact in the lives of people with cancer by addressing
unmet medical needs. AVEO’s proprietary Human Response PlatformTM
provides the company with unique insights into cancer and related
disease biology and is being leveraged in the discovery and clinical
development of its therapeutic candidates. For more information, please
visit the company’s website at www.aveooncology.com.
Source: AVEO Oncology
Investor Relations, 617-299-5810